European journal of obstetrics, gynecology, and reproductive biology · 2000
A population-based case-control teratologic study of oral oxytetracycline treatment during pregnancy.
СтатьяПоддержка исследования: вне правительства СШАНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Czeizel A E, Rockenbauer M
Аннотация
OBJECTIVE: To study human teratogenic potential of oral oxytetracycline treatment during pregnancy.
MATERIALS AND METHODS: The pair analysis of cases with congenital abnormalities and matched healthy controls in the large population-based dataset of the Hungarian Case-Control Surveillance of Congenital Abnormalities, 1980-1996.
RESULTS: Of 38,151 pregnant women who had babies without any defects in the study period (control group), 214 (0.6%) were treated with oral oxytetracycline. Of 22,865 pregnant women who had offspring with congenital abnormalities, 216 (0.9%) were treated with oxytetracycline (OR with 95%: 1.7, 1.4-2.0). Different approaches in the study showed a higher rate of medically documented oxytetracycline treatment in the second months of gestation in neural-tube defects (OR with 95%: 9.7, 2.0-47.1), cleft palate (17.2, 3.5-83.5) and multiple congenital abnormalities (12.9, 3.8-44.3) including mainly the combination of neural-tube defects and cardiovascular malformations.
CONCLUSION: Treatment with oxytetracycline during the second months of pregnancy presents a teratogenic risk to the fetus.
MATERIALS AND METHODS: The pair analysis of cases with congenital abnormalities and matched healthy controls in the large population-based dataset of the Hungarian Case-Control Surveillance of Congenital Abnormalities, 1980-1996.
RESULTS: Of 38,151 pregnant women who had babies without any defects in the study period (control group), 214 (0.6%) were treated with oral oxytetracycline. Of 22,865 pregnant women who had offspring with congenital abnormalities, 216 (0.9%) were treated with oxytetracycline (OR with 95%: 1.7, 1.4-2.0). Different approaches in the study showed a higher rate of medically documented oxytetracycline treatment in the second months of gestation in neural-tube defects (OR with 95%: 9.7, 2.0-47.1), cleft palate (17.2, 3.5-83.5) and multiple congenital abnormalities (12.9, 3.8-44.3) including mainly the combination of neural-tube defects and cardiovascular malformations.
CONCLUSION: Treatment with oxytetracycline during the second months of pregnancy presents a teratogenic risk to the fetus.